10.38
Precedente Chiudi:
$10.15
Aprire:
$9.98
Volume 24 ore:
118.75K
Relative Volume:
0.60
Capitalizzazione di mercato:
$359.12M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+5.49%
1M Prestazione:
+6.79%
6M Prestazione:
-58.01%
1 anno Prestazione:
+0.00%
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
1325 BOYLSTON STREET, BOSTON
Confronta RAPP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RAPP
Rapport Therapeutics Inc
|
10.38 | 359.12M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
2024-07-02 | Iniziato | Jefferies | Buy |
2024-07-02 | Iniziato | Stifel | Buy |
2024-07-02 | Iniziato | TD Cowen | Buy |
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World
Rapport Therapeutics to present data at 2025 AAN meeting - TipRanks
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire Inc.
Several Insiders Invested In Rapport Therapeutics Flagging Positive News - simplywall.st
Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock - Yahoo
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares - Yahoo Finance
Rapport Therapeutics director Wendy Young acquires $61,249 in stock By Investing.com - Investing.com India
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock - Investing.com
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock By Investing.com - Investing.com India
Rapport Therapeutics Executives Acquire Shares - TradingView
Rapport Therapeutics director Wendy Young acquires $61,249 in stock - Investing.com
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln - Nasdaq
Rapport Therapeutics, Inc. SEC 10-K Report - TradingView
Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year - TipRanks
Rapport Therapeutics Inc Q4 Net Loss $20.0 Million -March 11, 2025 at 07:20 am EDT - Marketscreener.com
Rhumbline Advisers Has $182,000 Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) On The My Stocks Page - Stock Traders Daily
Head of R&D Robert Lenz to leave Neumora - BioCentury
Rapport Therapeutics appoints new chief medical officer By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. Announces Appointment of Jeffrey Sevigny as Chief Medical Officer - Marketscreener.com
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - The Manila Times
Rapport Therapeutics appoints new chief medical officer - Investing.com
Rapport Therapeutics Announces Appointment of Dr. Jeffrey - GlobeNewswire
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
How To Trade (RAPP) - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat
Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Non sono disponibili dati finanziari per Rapport Therapeutics Inc (RAPP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):